Biotech

All Articles

New records show how Bayer's asundexian fell short to prevent strokes

.Bayer put on hold the period 3 trial for its variable XIa inhibitor asundexian late in 2013 after t...

Sanofi's tolebrutinib neglects 2 of 3 late-stage MS tests

.Sanofi is actually still bented on taking its own a number of sclerosis (MS) med tolebrutinib to th...

Galapagos' stock up as fund reveals intent to shape its own advancement

.Galapagos is actually coming under additional pressure from clients. Having actually developed a 9....

Cell- focused Sana gathers initial CSO-- Chutes &amp Ladders

.Welcome to this week's Chutes &amp Ladders, our roundup of substantial management hirings, shooting...

Allist pays off Jacobio $21M, landing task in Chinese KRAS race

.Shanghai Allist Pharmaceuticals has acquired on its own a starring character in China's KRAS market...

ReNeuron leaving intention swap after missing fundraising target

.ReNeuron has actually participated in the long listing of biotechs to leave behind Greater london's...

MBX apply for IPO to take challenger to Ascendis right into stage 3

.MBX Biosciences has added to the recent spurt of IPO filings. The biotech, which submitted its own ...

FDA extends probing right into Lykos' MDMA trials: WSJ

.For Lykos Therapeutics as well as the provider's prospective MDMA-assisted therapy for post-traumat...

Gene publisher Volume giving up 131 employees

.Merely times after gene publisher Tome Biosciences announced undisclosed operational slices, a more...

Repare gives up 25% of workers as biotech halts preclinical R&ampD

.Repare Therapy is actually laying off a quarter of its workforce as the oncology biotech lessen its...